Drug News

Novo Nordisk Parent Resubmits Catalent Deal Application to FTC

Novo Nordisk’s parent company, Novo Nordisk Foundation, has refiled its application to the U.S. Federal Trade Commission (FTC) seeking approval for its $16.5 billion acquisition of manufacturing subcontractor Catalent, a spokesperson announced on Monday.

The move comes after an earlier application submitted on March 4 was withdrawn following informal discussions with FTC staff. The new application was filed on April 2, as disclosed in a recent Catalent SEC filing dated April 3.

Last month, Novo Nordisk Foundation announced its intention to acquire Catalent to enhance production capabilities for its weight-loss drug Wegovy. As part of the agreement, three of Catalent’s fill-finish sites will be sold to Novo Nordisk for $11 billion post-acquisition.

When asked about the timeline for completing the deal, a spokesperson for Novo Nordisk declined to provide further details. However, the company confirmed that the resubmission of the application was intended to provide authorities with additional time for review.

Novo Nordisk had previously anticipated completing the acquisition by the end of 2024. However, given the recent developments, the timeline remains uncertain.

For further inquiries, Novo Nordisk Foundation can be contacted directly for comment on the reapplication process and any potential implications.


Joan David-Leonhard

Joan David Leonhard is a recent Pharm.D graduate with a strong passion for the pharmaceutical industry and a particular interest in pharmaceutical media and communication. Her brief internship experience includes roles in pharmacy where she built strong patient-pharmacist relationships and a pharmaceutical media internship where she actively contributed to drug information articles, blog posts, social media engagement, and various media projects.
Back to top button

Adblock Detected

Please consider supporting us by disabling your ad blocker